A news article by Scientific American explains how research at UMMS led to the discovery that cilia dysfunction causes polycystic kidney disease, which led to the discovery of other diseases now known as ciliopathies.
Katherine Fitzgerald, PhD, has been recognized by the International Cytokine and Interferon Society for her work in innate immunity, specifically in interferon production.
It’s been another banner year at UMass Medical School. Whether it was news about the Ebola crisis, the urgent need for increased NIH funding or recognition of the groundbreaking programs and scientists here, UMassMedNow kept the medical school community informed every day. Here are some of the biggest stories we covered in 2014. We’re looking forward to an even bigger 2015.
Drinking excessive amounts of alcohol this holiday may not make you an addict—according to a recent CDC report on the diagnostic criteria for alcoholism—but it will significantly damage your body. Dennis Dimitri, MD, explains the adverse effects of binge drinking in this Expert’s Corner.
UMass Medical School is involved in a new initiative, led by Diagnostics For All, to develop a rapid diagnostic test for Ebola. Such testing will make a ‘huge difference,’ according to Ebola survivor and physician Rick Sacra, who spoke at the State House press conference about the project.
Phillip D. Zamore, PhD, a pioneer in the study of RNA silencing, was named a 2014 Fellow of the National Academy of Inventors, a high professional distinction accorded to academic inventors who have demonstrated a prolific spirit of innovation.
MassBiologics of UMass Medical School and Voyager Therapeutics will collaborate on viral vector manufacturing at the new MassBiologics SouthCoast facility in Fall River.
A 60 Minutes report on mindfulness meditation features interviews with UMass Medical School’s Center for Mindfulness founder Jon Kabat-Zinn, PhD, and current faculty Judson Brewer, MD, PhD, and Jean King, PhD.
Infectious disease expert Robert Finberg, MD, said it is too early to predict whether Massachusetts will experience a severe flu season this year and urged families to get the vaccine.
While UMass Medical School psychiatrist Anthony Rothschild, MD, acknowledges that there is an urgent need for new antidepressant medications, he is cautious about the rising use of ketamine as a treatment for depression, as he told the New York Times for a Dec. 19 feature on the promising but controversial drug.